Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke

Stroke

Volumn 27, Issue 1, 1996, Pages 37-43

  Shinozaki, Kazuya ^a   Naritomi, Hiroaki ^a   Shimizu, Takao ^a   Suzuki, Masaaki ^a   Ikebuchi, Motoyoshi ^a   Sawada, Tohru ^a   Harano, Yutaka ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

atherosclerosis; cerebral ischemia; insulin; risk factors

Indexed keywords

APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN; OCTREOTIDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0030028633     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.1.37     Document Type: Article

References (56)

1. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131-141.
2. Welborn TA, Werarne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes. 1979;2:154-160.
3. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205-210.
4. Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb. 1991;11:80-90.
5. Gertler MM, Leetma HE, Koutrouby RJ, Johnson ED. The assessment of insulin, glucose and lipids in ischemic thrombotic cerebrovascular disease. Stroke. 1975;6:77-84.
6. Stout RW, Vallance-Owen J. Insulin and atheroma. Lancet. 1969;1: 1078-1080.
7. Harano Y, Kojima H, Kosugi K, Suzuki M, Harada M, Nakao T, Hidaka H, Kashiwagi A, Torii R, Taniguchi Y, Nishimori T, Yasuda Y, Shigeta Y. Hyperlipidemia and atherosclerosis in experimental insulinopenic diabetic monkeys. Diabetes Res Clin Pract. 1992;16: 163-173.
8. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317: 350-357.
9. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab. 1990;70:1114-1118.
10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for qualifying insulin secretion and resistance. Am J Physiol. 1979;273:E214-E223.
11. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231: 25-30.
12. Ooneda G. Pathology of stroke. Jpn Circ J. 1986;50:1224-1234.
13. Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19:1083-1092.
14. Challa VR, Bell MA, Moody DM. A combined hematoxylin-eosin, alkakine phosphatase and high-resolution microradiographic study of lacunes. Clin Neuropathol. 1990;9:196-204.
15. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol (Berl). 1969;12:1-15.
16. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Lobe BB, Gordon DL, Marsh EE, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
17. Fishman WH. Beta-adrenergic receptor blockers: adverse effects and drug interactions. Hypertension. 1988;11(suppl II):II-21-II-29.
18. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension. 1988;11(suppl II):II-16-II-20.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem. 1972;18: 499-502.
20. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Memorandum on classification of hyperlipidemias and hyperlipoproteinemias. Bull World Health Organ. 1970;43:891-898.
21. World Health Organization. Definition, Diagnosis, and Classification: Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985:9-25. Technical Report Series 727.
22. Hoffman WS. A rapid photoelectric method for the determination of glucose in blood and urine. J Biol Chem. 1937;120:52-55.
23. Hale CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963;88:137-146.
24. Richmond W. Preparation and properties of a cholesterol oxidase from Nacardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19:1350-1356.
25. Fletcher MJ. A colorimetric method for estimating serum triglycerides. Clin Chim Acta. 1968;22:393-397.
26. Didez LI. Separation and quantitation of subclasses of human plasma high density lipoproteins by a single precipitation procedure. J Lipid Res. 1982;23:1206-1223.
27. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Int J Immunochem. 1965;2:235-240.
28. Schuling J, Haan D, Limburg M, Groenier KH. The Frenchay Activities Index: assessment of functional status in stroke patients. Stroke. 1993;24:1173-1177.
29. Harano Y, Hidaka H, Takatsuki K, Ohgaku S, Haneda M, Motoi S, Shigeta Y, Abe H. Glucose, insulin, and somatostatin infusion for the determination of insulin sensitivity in vivo. Metabolism. 1978; 27(suppl I):1449-1452.
30. Harano Y, Kageyama A, Hirose J, Asakura Y. Yokota C, Ikebuchi M, Suzuki M, Omae T. Improvement of insulin sensitivity for glucose metabolism with long-acting Ca channel blocker, amlodipine in essential hypertensive subjects. Metabolism. 1995;44: 315-319.
31. Ikebuchi M, Suzuki M, Kageyama A, Hirose J, Yokota C, Ikeda K, Shinozaki K, Harano Y. Modified method using Sandostatin to assess in vivo insulin sensitivity. Endocr J. In press.
32. Nohta H, Mitsui A, Ohkura Y. Spectrofluorometric determination of catecholamines with 1,2-diphenylethylenediamine. Anal Chim Acta. 1984;165:171-176.
33. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care. In press.
34. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M, Harano Y. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation. 1995;92:1749-1757.
35. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994;25:1157-1164.
36. Bogousslavsky J, Regli F, Maeder P. Intracranial large-artery disease and 'lacunar' infarction. Cerebrovasc Dis. 1991;1:154-159.
37. Regensteiner JG, Mayer EJ, Shetterly SM, Eckel RH, Haskell WL, Marshall JA, Baxter J, Hamman RF. Relationship between habitual physical activity and insulin levels among nondiabetic men and women: San Luis Valley Diabetes Study. Diabetes Care. 1991; 14:1066-1074.
38. Lager I, Atvall S, Eriksson M, von Schenk H, Smith U. Studies on the insulin-antagonistic effect of catecholamines in normal man. Diabetologia. 1986;29:409-416.
39. Herderschee D, Hijdra A, Algra A, Koudstaal PJ, Kappeile LJ, van Gijn J. Silent stroke in patients with transient ischemic attack or minor ischemic stroke. Stroke. 1992;23:1220-1224.
40. Ricci S, Celani MG, La Rosa F, Righetti E, Duca E, Caputo N. Silent infarction in patients with first-ever stroke: a community-based study in Umbria, Italy. Stroke. 1993;24:647-651.
41. Mendez I, Hachinski V, Wolfe B. Serum lipids after stroke. Neurology. 1987;37:507-511.
42. Woo J, Lam CWK, Kay R, Wong HY, Teoh R, Nicholls MG. Acute and long-term changes in serum lipids after acute stroke. Stroke. 1990;21:1407-1441.
43. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-1076.
44. Marquie G. Effect of insulin in the induction and regression of experimental cholesterol atherosclerosis in the rabbit. Postgrad Med. 1978;54:80-85.
45. Cruz AB Jr, Amatuzio DS, Grande F, Hay LJ. Effect of intraarterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res. 1961;9:38-43.
46. Sato Y, Shiraishi S, Oshida Y, Ishiguro, Sakamoto N. Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes. 1989;38:91-96.
47. Stout RW. Development of vascular lesions in insulin-treated animals fed a normal diet. Br Med J. 1970;3:685-687.
48. Pfeifle B, Ditschuneit H. Two separate receptors for insulin and insulin-like growth factors on arterial smooth muscle cells. Diabetologia. 1981;20:155-158.
49. Stout RW. The effect of insulin and glucose on sterol synthesis in cultured rat arterial smooth muscle cells. Atherosclerosis. 1977;27: 271-278.
50. Oppenheimer MJ, Sundquist K, Bierman EL. Downregulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes. 1989;38:117-122.
51. Solberg LA, McGarry PA. Cerebral atherosclerosis in Negroes and Caucasians. Atherosclerosis. 1972;16:141-154.
52. Mathew NT, Davis D, Meyer JS, Chander K. Hyperlipoproteinemia in occlusive cerebrovascular disease. JAMA. 1975;232:262-266.
53. Harrison MJG, Wilson LA. Effect of blood pressure on prevalence of carotid atheroma. Stroke. 1983;14:550-551.
54. Crouse JR, Toole JF, McKinney WM, Dignan MB, Howard G, Kahl FR, McMahan MR, Harpold GH. Risk factors for extracranial carotid artery atherosclerosis. Stroke. 1987;18:990-996.
55. Reaven GM, Chen YDI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993;92: 141-146.
56. Harano Y, Nakao Y, Kageyama A, Suzuki M, Hirose J, Asakura Y, Sato A, Komatsu R, Tsushima M, Yamamoto A. Contribution of hyperinsulinemia and hyperglycemia to lipoprotein disorder in obesity. In: Oomura Y, Tarui S, Inoue S, Shimazu T, eds. Progress in Obesity Research. London, UK: John Libbey & Co Ltd; 1990:299-302.